20 completed, 12 terminated, 1 active not recruiting, 1 unknown. 34 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 34 | Completed 20, Terminated 12, Active not recruiting 1, Unknown 1 |
Follow Epoetin Alfa: new trials by email Literature Review of Epoetin Alfa trials Research Report on Epoetin Alfa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate the Efficacy and Safety of HIF-PHI for the Treatment of Anemia and Risks of Cardiovascular and Cerebrovascular Events in ESRD Newly Initiated Dialysis Patients HIF-PHI, Epoetin Alfa - Anemia in Incident Dialysis Patients | Phase 4 | Unknown | Second Xiangya Hospital of Central South University | 400 | 2022-10-20 | 2021-05-25 |
| Pharmacological Countermeasures for High Altitude Acetazolamide, Erythropoietin - Hypobaric Hypoxia | Phase 4 | Active not recruiting | United States Army Research Institute of Environmental Medicine | 18 | 2022-05-27 | 2025-03-26 |
| Impact of Erythropoietin on Hematological Adaptations and Physical Performance Epoetin Alfa - Exercise-Induced Anemia, Physical Performance | Phase 4 | Completed | United States Army Research Institute of Environmental Medicine | 8 | 2021-09-01 | 2025-04-18 |
| Biosimilar Erythropoietin in Anaemia Treatment (Correction Phase Study) EPIAO®, EPREX® - Renal Anaemia | Phase 4 | Terminated | Shenyang Sunshine Pharmaceutical Co., LTD. | 16 | 2015-08-01 | 2020-10-22 |
| Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis Epoetin alfa - Renal Insufficiency, Chronic, Anemia | Phase 4 | Completed | Amgen | 216 | 2015-04-01 | 2017-05-19 |
| Pre-operative Treatment With Erythropoietin and Iron Supplement in Cardiac Surgery Erythropoietin subcutaneously and Iron intravenously - Heart; Dysfunction Postoperative, Cardiac Surgery, Anemia, Iron-Deficiency | Phase 4 | Terminated | Catharina Ziekenhuis Eindhoven | 7 | 2014-08-01 | 2017-04-05 |
| Impact of Preoperative Treatment of Anemia and Iron Deficiency in Cardiac Surgery on Outcome. Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid - Anemia, Iron Deficiency | Phase 4 | Completed | University of Zurich | 1003 | 2013-12-01 | 2018-05-11 |
| Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis Peginesatide, Epoetin alfa - Anemia | Phase 4 | Terminated | Amgen | 41 | 2012-10-01 | 2014-04-21 |
| Comparison Among Erythropoietin Stimulating Agents Epoetin alpha or beta (Epoetin group), Darbepoetin alfa, Methoxy polyethylene glycol-epoetin beta - Anemia of End Stage Renal Disease | Phase 4 | Completed | Hamad Medical Corporation | 327 | 2012-03-01 | 2017-09-13 |
| Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia Epoetin alfa - Antineoplastic Chemotherapy Induced Anemia | Phase 4 | Completed | Bio Sidus SA | 30 | 2011-06-01 | 2016-04-07 |
| Cost Comparison Study of Darbepoetin Versus Epoetin Therapy to Treat Anemia in Hemodialysis Patients Epoetin Alfa, Darbepoetin alfa - Anemia, Chronic Kidney Disease | Phase 4 | Completed | Andrea L Woodland | 50 | 2010-09-01 | 2019-09-10 |
| A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs) Darbepoetin Alfa, Epoetin Alfa, Epoetin Beta - Chronic Renal Anemia | Phase 4 | Completed | Hoffmann-La Roche | 2825 | 2008-12-12 | 2019-08-20 |
| Post-authorization Safety Study in CKD Subjects Receiving HX575 i.v. HX575 recombinant human erythropoietin alfa - Chronic Kidney Disease | Phase 4 | Completed | Sandoz | 1695 | 2008-07-01 | 2017-07-11 |
| Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa Epoetin alfa, Saline - Subarachnoid Hemorrhage | Phase 4 | Terminated | University of South Florida | 3 | 2007-07-01 | 2018-07-31 |
| Effect of Procrit (Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation Epoetin Alfa - Delayed Graft Function | Phase 4 | Completed | West Penn Allegheny Health System | 76 | 2007-02-01 | 2010-05-27 |
| The Safety and Effectiveness of PROCRIT (Epoetin Alfa) in Patients Undergoing Elective Major Abdominal and/or Pelvic Surgery Epoetin alfa, Standard of Care - Hemostasis, Surgical | Phase 4 | Terminated | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 37 | 2006-08-01 | 2013-07-22 |
| A Safety Study of Epoetin Alfa in Patients With Cancer Who Have Chemotherapy-Related Anemia Epoetin alfa 450 IU/kg once a week, Epoetin alfa 150 IU/kg 3 times a week, Epoetin alfa 450 IU/kg once a week (QW) - Anemia, Neoplasms | Phase 4 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 504 | 2006-01-01 | 2012-04-05 |
| Prevalence and Treatment of Anemia in Rehabilitation Patients placebo, epoetin alpha, Niferex - Anemia | Phase 4 | Terminated | University of Medicine and Dentistry of New Jersey | 22 | 2005-11-01 | 2014-01-31 |
| Erythropoietin in Radiocontrast Induced Nephropathy (ERIN) Trial erythropoeitin - Contrast Induced Nephropathy | Phase 4 | Terminated | Brigham and Women's Hospital | 17 | 2004-09-01 | 2009-04-06 |
| Blood Management in Orthopedic Surgery erythropoietin and cell saver, erythropoietin, OrthoPAT - Osteoarthritis | Phase 4 | Completed | Sanquin Research & Blood Bank Divisions | 2598 | 2004-05-01 | 2009-10-20 |
Showing 20 of 34. Sign in to see all of them.
Anemia (21) · Renal Insufficiency, Chronic (7) · Kidney Failure, Chronic (5) · Neoplasms (5) · Kidney Diseases (2) · Acquired Immunodeficiency Syndrome (1) · Acute Kidney Injury (1) · Anemia, Iron-Deficiency (1) · Aneurysm (1) · Breast Neoplasms (1) · Delayed Graft Function (1) · Fatigue (1) · HIV Infections (1) · Hypertrophy, Left Ventricular (1) · Iron Deficiencies (1)
Ortho Biotech Products, L.P. (5) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (3) · Amgen (2) · Janssen-Cilag B.V. (2) · Ortho Biotech, Inc. (2) · United States Army Research Institute of Environmental Medicine (2) · University of Zurich (2) · Andrea L Woodland (1) · Bio Sidus SA (1) · Brigham and Women's Hospital (1) · Catharina Ziekenhuis Eindhoven (1) · Hamad Medical Corporation (1) · Hoffmann-La Roche (1) · Janssen Cilag S.A.S. (1) · Janssen Pharmaceutica N.V., Belgium (1)
United States (8) · Argentina (2) · France (2) · Germany (2) · Italy (2) · Netherlands (2) · Poland (2) · Russia (2) · Thailand (2) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · China (1)
Ajay K Singh, M.D. (1) · Andrea L Woodland, BScPharm,MSc (1) · Donat R Spahn, Prof MD (1) · Enrico M Camporesi, MD (1) · Fadwa S. AL-Ali, MD (1) · Jeffrey L Carson, MD (1)
PMID 36791280, PMID 15953714, PMID 16177289, PMID 16977654, PMID 17108343, PMID 17400086, PMID 18284320, PMID 18343652, PMID 22732334, PMID 22745272, PMID 28717516, PMID 31036337, PMID 31420350, PMID 31668348, PMID 36005278, PMID 38757249, PMID 39301879